All In Biotech

Drug Trial Radar · NCT07446998

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 239 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

239

Actual

Start

Mar 26, 2026

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Veru Inc.Industry
Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the effect of enobosarm on total body weight

Conditions

  • Obesity & Overweight
  • Mobility Disability
  • HOMA-IR

Interventions

  • EnobosarmDrug

    Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.

  • Semaglutide (Wegovy) weekly injectionDrug

    Semaglutide for Chronic Weight Management

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.Time frame: Day 476

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • DM Clinical Research - Phoenix

    Phoenix, Arizona

  • DM Clinical Research - MIA

    Doral, Florida

  • Universal Axon Clinical Research (Rovia - UACR)

    Doral, Florida

  • Paramo Health

    Miami, Florida

  • IMIC Research a Rovia Clinical Research Company

    Miami, Florida

  • Paramo Health

    Miami, Florida

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

  • Centennial Medical Group (CMG)

    Columbia, Maryland

  • SKY Integrative Medical Center

    Ridgeland, Mississippi

  • ALSA Research

    New York, New York

  • Coastal Research Institute, LLC

    Fayetteville, North Carolina

  • DM Clinical - Dallas

    Irving, Texas

  • DM Clinical - Seattle

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.